Anesthesia in HIV-infected children.
In 2005, it was estimated that 2.3 million children below 15 years of age were living with human immunodeficiency virus (HIV)/AIDS and 570,000 children below 15 years died. Maternal-infant or vertical transmission is the most common mode of HIV infection in children. As transplacental passage of maternal anti-HIV antibodies, diagnosis of HIV infection in young infants relies on virologic assays. Infants older than 18 months of age can be diagnosed by serology alone. Pediatric HIV infections are classified according to Center for Disease Control and Prevention 1994 revised classification system. The understanding of viral pathogenesis, the development of highly active antiretroviral therapy, and the ability to quantitate viral burden have led to significant reduction in disease progression and morbidity in HIV-infected children. As survival improves, these children will require anesthesia care and pain treatment during the course of their illness. Considerations for the anesthesiologist include: possible involvement of multiple organ systems, adverse reactions and drug interactions of antiretroviral agents and adequate infection control to prevent HIV transmission in hospital and other infections to the immunocompromised patients. Finally, care should be taken not to violate confidentiality.
Leelanukrom
Ruenreong
R
Department of Anesthesiology, Chulalongkorn University, Bangkok, Thailand. leelanukrom@hotmail.com
Pancharoen
Chitsanu
C
D000293:Adolescent; D000758:Anesthesia / Q000379:methods*; D000777:Anesthetics / Q000009:adverse effects*; D044966:Anti-Retroviral Agents / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007223:Infant; D017053:Infection Control; D017758:Infectious Disease Transmission, Patient-to-Professional / Q000517:prevention & control; D010146:Pain / Q000150:complications / Q000517:prevention & control*; D012307:Risk Factors
D000777:Anesthetics; D044966:Anti-Retroviral Agents